Prescription and Over-the-Counter Drug Product List 35TH EDITION

Cumulative Supplement Number 02: February 2015

		ACETAMINOPHEN; BUTALBITAL; CAFFEIN	JF.							
		TABLET;ORAL	<u></u>							
		FIORICET								
>A>		@ ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616						
>D>		@ WATSON PHARMS	325MG;50MG;40MG	A088616	001	Nov	09,	1984	Feb	CAHN
		ACETAMINOPHEN; HYDROCODONE BITARTE	RATE							
		TABLET; ORAL								
		HYDROCODONE BITARTRATE AND ACE								
>D>		+ MIKART	325MG; 2.5MG	A040846			-			CTEC
>A>	AA	+ NORCO	325MG;2.5MG	A040846	001	Jun	09,	2010	r'eb	CTEC
>A>	AA	ACTAVIS LABS FL INC	325MG;2.5MG	A040148	004	Jul	07,	2014	Feb	NEWA
>A>	AA		325MG;5MG	A040148	005	Jul	07,	2014	Feb	NEWA
		ALFUZOSIN HYDROCHLORIDE								
		TABLET, EXTENDED RELEASE; ORAL								
		ALFUZOSIN HYDROCHLORIDE								
>D>	AB	WOCKHARDT LTD	10MG	A090221		_				DISC
>A>		@	10MG	A090221	001	Aug	10,	2012	Feb	DISC
		AMINO ACIDS								
		INJECTABLE; INJECTION								
>D>		BRANCHAMIN 4% IN PLASTIC CONTA								
>D>		BAXTER HLTHCARE	4% (4GM/100ML)	N 018684		-	-			
>A>		@	4% (4GM/100ML)	N018684	001	Sep	28,	1984	Feb	DISC
		AMINO ACIDS; MAGNESIUM CHLORIDE;	POTASSIUM PHOSPHATE, DIBASIC; S	ODIUM ACETAT	ΓΕ; S	ODIU	м сн	LORIDE	1	
		INJECTABLE; INJECTION								
>D>		TRAVASOL 3.5% SULFITE FREE W/ :	ELECTROLYTES IN PLASTIC CONTAIN	IER						
>D>		BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;	218 N 020177	001	Oct	23,	1995	Feb	DISC
>A>		@	MG/100ML; 35MG/100ML	010 2 000177	0.01		0.0	1005	Fob	DISC
		e	3.5%;51MG/100ML;131MG/100ML; MG/100ML;35MG/100ML	218 N U 2 U 1 / /	001	Oct	23,	1995	reb	DISC
			MG/100ML; 35MG/100ML	218 N U2U1//	001	Oct	23,	1995	reb	DISC
		ATENOLOL		218 N U 2 U 1 / /	001	Oct	23,	1995	reb	DISC
		ATENOLOL TABLET; ORAL		218 N U 2 U 1 / /	001	Oct	23,	1993	reb	DISC
>A>	AB	ATENOLOL								CAHN
>A> >A>		ATENOLOL TABLET; ORAL TENORMIN	MG/100ML;35MG/100ML	N 018240 N 018240	004	Apr	09,	1990	Feb	
	AB	ATENOLOL TABLET; ORAL TENORMIN	MG/100ML;35MG/100ML	N 018240	004	Apr Aug	09,	1990 1981	Feb Feb	CAHN
>A>	AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL	MG/100ML;35MG/100ML 25MG 50MG	N 018240 N 018240 N 018240 N 018240	004 001 002 004	Apr Aug Aug Apr	09, 19, 19,	1990 1981 1981 1990	Feb Feb Feb	CAHN CAHN CAHN CAHN
>A> >A>	AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL	MG/100ML;35MG/100ML 25MG 50MG 100MG	N 018240 N 018240 N 018240	004 001 002 004	Apr Aug Aug Apr	09, 19, 19,	1990 1981 1981 1990	Feb Feb Feb	CAHN CAHN CAHN CAHN
>A> >A> >D>	AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA	MG/100ML;35MG/100ML 25MG 50MG 100MG 25MG	N 018240 N 018240 N 018240 N 018240	004 001 002 004 001	Apr Aug Aug Apr	09, 19, 19,	1990 1981 1981 1990 1981	Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D>	AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG	N 018240 N 018240 N 018240 N 018240 N 018240	004 001 002 004 001	Apr Aug Aug Apr	09, 19, 19,	1990 1981 1981 1990 1981	Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D>	AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA +	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG	N 018240 N 018240 N 018240 N 018240 N 018240	004 001 002 004 001	Apr Aug Aug Apr	09, 19, 19,	1990 1981 1981 1990 1981	Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D>	AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG	N 018240 N 018240 N 018240 N 018240 N 018240	004 001 002 004 001	Apr Aug Aug Apr	09, 19, 19,	1990 1981 1981 1990 1981	Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D> >D> >D> >A>	AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240	004 001 002 004 001 002	Apr Aug Apr Aug Aug	09, 19, 19, 09, 19,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D> >D>	AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240	004 001 002 004 001 002	Apr Aug Apr Aug Aug	09, 19, 19, 09, 19,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D> >D> >D> >D>	AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240 N 018760	004 001 002 004 001 002	Apr Aug Apr Aug Aug Jun	09, 19, 19, 09, 19,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >D> >A>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG 50MG 100MG; 25MG 50MG; 25MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240 N 018760 N 018760	004 001 002 004 001 002	Apr Aug Apr Aug Aug Jun Jun	09, 19, 19, 09, 19, 08,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >D> >D> >D> >D> >D>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240 N 018760	004 001 002 004 001 002	Apr Aug Apr Aug Aug Jun Jun	09, 19, 19, 09, 19, 08,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >D> >A>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG 100MG; 25MG 50MG; 25MG 50MG; 25MG 50MG; 25MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240 N 018760 N 018760	004 001 002 004 001 002	Apr Aug Apr Aug Aug Jun Jun	09, 19, 19, 09, 19, 08,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >D> >A>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ATROPINE SULFATE; DIFENOXIN HYDROG TABLET; ORAL	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG 100MG; 25MG 50MG; 25MG 50MG; 25MG 50MG; 25MG	N 018240 N 018240 N 018240 N 018240 N 018240 N 018240 N 018760 N 018760	004 001 002 004 001 002	Apr Aug Apr Aug Aug Jun Jun	09, 19, 19, 09, 19, 08,	1990 1981 1981 1990 1981 1981	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >A> >D> >D>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ATROPINE SULFATE; DIFENOXIN HYDROG TABLET; ORAL MOTOFEN	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG; 25MG 100MG; 25MG 50MG; 25MG 50MG; 25MG	N018240 N018240 N018240 N018240 N018240 N018240 N018760 N018760 N018760	004 001 002 004 001 002	Apr Aug Apr Aug Aug Jun Jun	09, 19, 19, 09, 19, 19,	1990 1981 1981 1990 1981 1981 1984 1984	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >D> >A> >A> >A> >A>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ATROPINE SULFATE; DIFENOXIN HYDROG TABLET; ORAL MOTOFEN + SEBELA IRELAND LTD	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG 100MG; 25MG 100MG; 25MG 50MG; 25MG 50MG; 25MG 50MG; 25MG	N018240 N018240 N018240 N018240 N018240 N018240 N018760 N018760 N018760	004 001 002 004 001 002	Apr Aug Apr Aug Jun Jun Jun	09, 19, 19, 09, 19, 19, 08, 08,	1990 1981 1981 1990 1981 1981 1984 1984	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >A> >D> >D>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ATROPINE SULFATE; DIFENOXIN HYDROC TABLET; ORAL MOTOFEN + SEBELA IRELAND LTD + VALEANT	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG; 25MG 100MG; 25MG 50MG; 25MG 50MG; 25MG	N018240 N018240 N018240 N018240 N018240 N018240 N018760 N018760 N018760	004 001 002 004 001 002	Apr Aug Apr Aug Jun Jun Jun	09, 19, 19, 09, 19, 19, 08, 08,	1990 1981 1981 1990 1981 1981 1984 1984	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >D> >A> >D> >A> >D> >A> >D>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ATROPINE SULFATE; DIFENOXIN HYDROCOME TABLET; ORAL MOTOFEN + SEBELA IRELAND LTD + VALEANT MOTOFEN HALF-STRENGTH	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG 100MG; 25MG 100MG; 25MG 50MG; 25MG 50MG; 25MG 50MG; 25MG 50MG; 25MG	N018240 N018240 N018240 N018240 N018240 N018240 N018760 N018760 N018760 N018760	004 001 002 004 001 002 002 002	Apr Aug Apr Aug Jun Jun Jun Jun	09, 19, 19, 09, 19, 19, 08, 08,	1990 1981 1981 1990 1981 1981 1984 1984 1984	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >D> >D> >A> >A> >A> >A>	AB AB AB AB AB AB	ATENOLOL TABLET; ORAL TENORMIN ALVOGEN IPCO SARL + ASTRAZENECA + ATENOLOL; CHLORTHALIDONE TABLET; ORAL TENORETIC 100 + ALVOGEN IPCO SARL + ASTRAZENECA TENORETIC 50 ALVOGEN IPCO SARL ASTRAZENECA ATROPINE SULFATE; DIFENOXIN HYDROC TABLET; ORAL MOTOFEN + SEBELA IRELAND LTD + VALEANT	MG/100ML; 35MG/100ML 25MG 50MG 100MG 25MG 50MG 100MG 100MG 100MG; 25MG 100MG; 25MG 50MG; 25MG 50MG; 25MG 50MG; 25MG	N018240 N018240 N018240 N018240 N018240 N018240 N018760 N018760 N018760	004 001 002 004 001 002 001 002 002 002	Apr Aug Apr Aug Jun Jun Jun Jun	09, 19, 19, 09, 19, 19, 08, 08, 14, 14,	1990 1981 1981 1990 1981 1981 1984 1984 1984 1978	Feb Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN

>A>		AVIBACTAM SODIUM; CEFTAZIDIME								
>A>		POWDER; IV (INFUSION)								
>A> >A>		AVYCAZ + CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N 206494	0.01	Foh	25	2015	Feb	NEWA
/H/		T CEREAA INC	EQ U.JGM BASE, ZGM/ VIAL	N 200494	001	ren	23,	2015	reb	NEWA
		BETHANECHOL CHLORIDE								
		TABLET; ORAL								
		BETHANECHOL CHLORIDE								
>D>		@ LANNETT HOLDINGS INC	5MG	A040703	001	Mar	27,	2008	Feb	CMFD
>A>	AA		5MG	A040703	001	Mar	27,	2008	Feb	CMFD
>D>		@	50MG	A040677	001	Mar	27,	2008	Feb	CMFD
>A>	AA		50MG	A040677	001	Mar	27,	2008	Feb	CMFD
		BIMATOPROST								
		SOLUTION/DROPS; OPHTHALMIC								
>A>		BIMATOPROST								
>A>	AΤ	+ LUPIN LTD	0.03%	A203991	001	Feb	20,	2015	Feb	NEWA
		BUPRENORPHINE HYDROCHLORIDE								
		TABLET; SUBLINGUAL								
	3.5	BUPRENORPHINE HYDROCHLORIDE	EO OMO DIGE	3.000010	0.01	m . 1.	1.0	0015	- I- I-	117777
>A>		ACTAVIS ELIZABETH	EQ 2MG BASE	A 0 9 0 8 1 9			-			
>A>		MVI ANI DIIADMO TNO	EQ 8MG BASE	A 0 9 0 8 1 9			-		Feb	
>A>		MYLAN PHARMS INC	EQ 2MG BASE	A 201066			-		Feb	
>A>	AB		EQ 8MG BASE	A201066	002	Mar	06,	2015	Feb	NEWA
		BUPROPION HYDROBROMIDE								
		TABLET, EXTENDED RELEASE; ORAL								
		APLENZIN								
>D>		VALEANT BERMUDA	174MG	N 022108	001	Apr	23.	2008	Feb	CAHN
>D>			348MG	N 022108		_				CAHN
>D>		+	522MG	N 022108		-	-			CAHN
>A>		VALEANT PHARMS NORTH	174MG	N 022108		_				CAHN
>A>			348MG	N 022108		_				CAHN
>A>		+	522MG	N 022108		-	-			CAHN
						1	- ,			
>D>		CALCIUM CHLORIDE; DEXTROSE; LACTI	C ACID; MAGNESIUM CHLORIDE; PO	TASSIUM CHLO	RIDE;	SOD	IUM	BICARE	BONATE	<u>;</u>
		SODIUM CHLORIDE; SODIUM PHOSPHATE								
>D>		INJECTABLE; INJECTION								
>D>		PHOXILLUM B22K 4/0 IN PLASTIC				_		0045	_ ,	
>D>		+ GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1 L; 3.05GM/1000ML; 0.314GM/100		002	Jan	13,	2015	F'eb	CAIN
			2.21GM/1000ML; 6.95GM/1000ML							
			87GM/1000ML (5000ML)	,, , , ,						
>D>		PHOXILLUM BK 4/2.5 IN PLASTIC								
>D>		+ GAMBRO LUNDIA	3.68GM/1000ML; N/A/1000ML; N/		001	Jan	13,	2015	Feb	CAIN
			00ML;3.05GM/1000ML;0.314GM/	1000						
			;3.09GM/1000ML;6.34GM/1000M	1L;0.						
			187GM/1000ML (5000ML)							
>A>		CALCIUM CHLORIDE; MAGNESIUM CHLOR	IDE; POTASSIUM CHLORIDE; SODIU	M BICARBONATI	E; SC	DIUM	CHI	ORIDE	: SODI	<u>UM</u>
>A>		PHOSPHATE INJECTABLE; INJECTION								
>A>		PHOXILLUM B22K 4/0 IN PLASTIC	CONTAINER							
>A>		+ GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.	314G N 207026	002	Jan	13.	2015	Feb	CATN
			M/1000ML; 2.21GM/1000ML; 6.95				,			
			000ML;0.187GM/1000ML (5000M	ſL)						
>A>		PHOXILLUM BK 4/2.5 IN PLASTIC		0 0 2200 7000	0.01	_	1.0	0015	- 1	~~
>A>		+ GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML 14GM/1000ML	1; U.3 N Z U / U Z 6	001	Jan	13,	2015	reb	CAIN
			;3.09GM/1000ML;6.34GM/1000M	ML; 0.						
			187GM/1000ML (5000ML)	•						
		CANDESARTAN CILEXETIL; HYDROCHLOR	<u>OTHIAZIDE</u>							
		TABLET; ORAL								
, -		CANDESARTAN CILEXETIL AND HYDE		- 00	00-		0 =	004 =		
>A>		MACLEODS PHARMS LTD	16MG;12.5MG	A 204100						
>A>			32MG;12.5MG	A 204100						NEWA

32MG;25MG

A204100 003 Feb 27, 2015 Feb NEWA

>A> AB

CHLORPROMAZINE HYDROCHLORIDE

		INJECTABLE; INJECTION							
		CHLORPROMAZINE HYDROCHLORIDE							
>A>		+ EUROHLTH INTL SARL	25MG/ML	A083329	001	Jul 25,	1974	Feb	CAHN
>D>		+ HIKMA MAPLE	25MG/ML	A083329	001	Jul 25,	1974	Feb	CAHN
		CISATRACURIUM BESYLATE							
		INJECTABLE; INJECTION							
		CISATRACURIUM BESYLATE							
>A>	ΑP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26,	2015	Feb	NEWA
		CISATRACURIUM BESYLATE PRESERVA							
>A>	AP	FRESENIUS KABI USA			001	Feb 26,	2015	Feb	NEWA
>A>	AP		EQ 10MG BASE/ML	A203182	002	Feb 26,	2015	Feb	NEWA
		CLOBETASOL PROPIONATE							
		OINTMENT; TOPICAL							
		CLOBETASOL PROPIONATE							
>A>			0.05%	A074089					
>D>	AB	TEVA PHARMS	0.05%	A074089	001	Feb 16,	1994	Feb	CAHN
		CYANOCOBALAMIN							
		INJECTABLE; INJECTION							
		CYANOCOBALAMIN							
>A>			1MG/ML	A080515					
>D>		@ HIKMA MAPLE	1MG/ML	A080515	002	Oct 20,	1971	Feb	CAHN
		DEXAMETHASONE SODIUM PHOSPHATE							
		INJECTABLE; INJECTION							
		DEXAMETHASONE SODIUM PHOSPHATE							
>A>	AP	+ EUROHLTH INTL SARL	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07,	1982	Feb	CAHN
>D>	AP	+ HIKMA MAPLE	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07,	1982	Feb	CAHN
		DIATRIZOATE MEGLUMINE; DIATRIZOATE	SODIUM						
		INJECTABLE; INJECTION							
		MD-76R							
		+ LIEBEL-FLARSHEIM		N 019292					
>D>	AP	+ MALLINCKRODT	66%;10%	N019292	001	Sep 29,	1989	F'eb	CAHN
		DIGOXIN							
		INJECTABLE; INJECTION							
		DIGOXIN	0.05.00/0-	- 000001	004		4000		
>A>				A 083391	001	Oct 24,	1975	Feb	CAHN
>D>	AP		0.25MG/ML	A083391	001	Oct 24,	1975	Feb	CAHN
		TABLET;ORAL DIGOXIN							
>D>			0 125MG	A076363	001	.Tan 31	2003	Feh	CMED
>A>			0.125MG 0.125MG	A076363					
>D>			0.25MG	A076363					
>A>			0.25MG	A076363		-			
- 11/	سدد		0.20110	11010303	002	Jun J1,	2000	- (1)	OLIL D

		DILTIAZEM HYDROCHLORIDE								
		CAPSULE, EXTENDED RELEASE; ORAL								
>D>		DILACOR XR								
	AB2		120MG	N 020092		_				
>A>		@	120MG	N 020092		-			Feb	
>D>	AB2		180MG	N 020092		_			Feb	
>A>		@	180MG	N 020092		-	-		Feb	
		+	240MG	N 020092		-			Feb	
>A>		@	240MG	N020092	003	мау	29,	1992	der	DISC
>D>	AB2	DILTIAZEM HYDROCHLORIDE MYLAN	240MG	A075124	0.01	Mar	1 Ω	1000	Foh	CRLD
		+	240MG	A075124						CRLD
/ []	ADZ	TIAZAC	240116	AU/JIZ4	001	riai	10,	1000	reb	CKID
>D>	AB4		120MG	N020401	001	Sep	11.	1995	Feb	CAHN
	AB4		180MG	N 020401		_				CAHN
>D>	AB4		240MG	N020401		-			Feb	CAHN
>D>	AB4		300MG	N020401		_			Feb	CAHN
>D>	AB4		360MG	N020401		-	-			CAHN
>D>	AB4	+	420MG	N020401	006	Oct	16,	1998	Feb	CAHN
>A>	AB4	VALEANT PHARMS NORTH	120MG	N020401	001	Sep	11,	1995	Feb	CAHN
>A>	AB4		180MG	N020401	002	Sep	11,	1995	Feb	CAHN
>A>	AB4		240MG	N020401	003	Sep	11,	1995	Feb	CAHN
>A>	AB4		300MG	N020401	004	Sep	11,	1995	Feb	CAHN
>A>	AB4		360MG	N020401	005	Sep	11,	1995	Feb	CAHN
>A>	AB4	+	420MG	N020401	006	Oct	16,	1998	Feb	CAHN
		DISULFIRAM								
		TABLET; ORAL								
		DISULFIRAM	05000	- 000046	004			0045	_ ,	
>A>		MYLAN PHARMS INC	250MG	A 203916			-			
>A>	AB		500MG	A203916	002	Mar	04,	2015	r'eb	NEWA
		ESMOLOL HYDROCHLORIDE								
		INJECTABLE; INJECTION								
		ESMOLOL HYDROCHLORIDE								
>A>	AP	LUITPOLD	10MG/ML	A201126	001	Feb	20,	2015	Feb	NEWA
		ETHINYL ESTRADIOL; LEVONORGESTREL								
		ETHINYL ESTRADIOL; LEVONORGESTREL TABLET; ORAL								
>A>										
>A> >A>		TABLET; ORAL	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb	23,	2015	Feb	NEWA
	AB	TABLET;ORAL ASHLYNA GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb	23,	2015	Feb	NEWA
	AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN		A203163	001	Feb	23,	2015	Feb	NEWA
>A>	AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN		A203163	001	Feb	23,	2015	Feb	NEWA
>A> >D>	AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAI ORTHO EVRA								
>A>	AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAL ORTHO EVRA + JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N 021180	001	Nov	20,	2001	Feb	DISC
>A> >D>	AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAI ORTHO EVRA			001	Nov	20,	2001		DISC
>A>	AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAL ORTHO EVRA + JANSSEN PHARMS @	0.035MG/24HR;0.15MG/24HR	N 021180	001 001	Nov Nov	20,	2001	Feb Feb	DISC
>A> >D> >D> >A>	AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAL ORTHO EVRA + JANSSEN PHARMS @ XULANE	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N 021180 N 021180	001 001	Nov Nov Apr	20, 20,	2001 2001 2014	Feb Feb	DISC DISC CRLD
>A> >D> >D> >A> >D> >A>	AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N021180 N021180 A200910	001 001	Nov Nov Apr	20, 20,	2001 2001 2014	Feb Feb Feb	DISC DISC CRLD
>A> >D> >D> >A> >D> >A>	AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N021180 N021180 A200910	001 001	Nov Nov Apr	20, 20,	2001 2001 2014	Feb Feb Feb	DISC DISC CRLD
>A> >D> >D> >A> >D> >A>	AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES +	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N021180 N021180 A200910	001 001	Nov Nov Apr	20, 20,	2001 2001 2014	Feb Feb Feb	DISC DISC CRLD
>A> >D> >D> >A> >D> >A>	AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N021180 N021180 A200910 A200910	001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014	Feb Feb Feb	DISC DISC CRLD CRLD
>A> >D> >D> >A> >A> >A>	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N 021180 N 021180 A 200910 A 200910	001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014	Feb Feb Feb	DISC DISC CRLD CRLD
>A> >D> >D> >A> >D> >A>	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS	0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR	N021180 N021180 A200910 A200910	001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014	Feb Feb Feb	DISC DISC CRLD CRLD
>A> >D> >D> >A> >D> >A> >D> >A> >D> >A>	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565	001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014 1974	Feb Feb Feb Feb	DISC DISC CRLD CRLD
>A> >D> >D> >A> >A> >A>	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565	001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014 1974	Feb Feb Feb Feb	DISC DISC CRLD CRLD
>A> >D> >D> >A> >D> >A> >D> >A> >D> >A>	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977	001 001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014 1974 1974	Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN
>A> >D> >D> >A> >A> >A> >A> >A> >	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977	001 001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014 1974 1974	Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN
>A> >D> >D> >A> >A> >A> >A> >A> >	AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977	001 001 001 001 001	Nov Nov Apr Apr	20, 20, 16, 16,	2001 2001 2014 2014 1974 1974	Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN
>A> >D> >D> >A> >A> >D> >A> >D> >A> >A	AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977	001 001 001 001 001 001	Nov Nov Apr Apr Dec Dec	20, 20, 16, 16,	2001 2001 2014 2014 1974 1974 1984	Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN
>A> >D> >D> >A> >A> >D> >A> >A> >A> >	AB AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977 N 018977	001 001 001 001 001 001	Nov Nov Apr Apr Dec Apr	20, 20, 16, 16, 27, 27, 13,	2001 2001 2014 2014 2014 1974 1984 1984	Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN CAHN
>A> >D> >D> >A> >A> >D> >A> >D> >A> >A	AB AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977	001 001 001 001 001 001	Nov Nov Apr Apr Dec Apr	20, 20, 16, 16, 27, 27, 13,	2001 2001 2014 2014 2014 1974 1984 1984	Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN
>A> >D> >D> >A> >D> >A> >D> >A> >A> >D> >A> >D> >A> >D> >A> >D> >A> >D>	AB AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 28-DAY	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977 N 018977	001 001 001 001 001 001 002 002	Nov Nov Apr Apr Dec Apr Dec	20, 20, 16, 16, 27, 27, 13,	2001 2001 2014 2014 2014 1974 1984 1984	Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN CAHN
>A> >D> >D> >A> >A> >D> >A> >A> >A> >	AB AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977 N 018977	001 001 001 001 001 001 002 002	Nov Nov Apr Apr Dec Apr Dec	20, 20, 16, 16, 27, 27, 13,	2001 2001 2014 2014 2014 1974 1984 1984	Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN CAHN
>A> >D> >D> >A> >D> >A> >D> >A> >A> >D> >A> >D> >A> >D> >A> >D> >A> >D>	AB AB AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 28-DAY	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977 N 017565 N 017565	001 001 001 001 001 001 002 002	Nov Nov Apr Apr Dec Apr Dec Apr	20, 20, 16, 16, 27, 27, 13, 27, 27,	2001 2001 2014 2014 2014 1974 1984 1974 1984	Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN CAHN CAHN CAHN
>A> >D> >D> >D> >A> >A> >A> >A> >A	AB AB AB AB AB AB AB	TABLET; ORAL ASHLYNA GLENMARK GENERICS ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE; TRANSDERMAN ORTHO EVRA + JANSSEN PHARMS @ XULANE MYLAN TECHNOLOGIES + ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL-21 NORINYL 1+35 21-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 21-DAY @ ACTAVIS LABS UT INC @ WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TABLET; ORAL-28 NORINYL 1+35 28-DAY ACTAVIS LABS UT INC WATSON LABS TRI-NORINYL 28-DAY + ACTAVIS LABS UT INC	0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG/24HR; 0.15MG/24HR 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG, 0.035MG, 0.035MG; 0.5MG, 1 MG, 0.5MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG 0.035MG; 1MG	N 021180 N 021180 A 200910 A 200910 N 017565 N 017565 N 018977 N 017565 N 017565	001 001 001 001 001 001 002 002	Nov Nov Apr Apr Dec Apr Dec Apr	20, 20, 16, 16, 27, 27, 13, 27, 27,	2001 2001 2014 2014 2014 1974 1984 1974 1984	Feb Feb Feb Feb Feb Feb Feb	DISC DISC CRLD CRLD CAHN CAHN CAHN CAHN CAHN CAHN

		ETHINYL ESTRADIOL; NORETHINDRONE TABLET; ORAL	ACETATE							
>A>		LARIN 24 FE								
		NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb	18,	2015	Feb	NEWA
		TABLET;ORAL-21								
		NORETHINDRONE ACETATE AND ETHI	INYL ESTRADIOL							
>A>	AB	FAMY CARE LTD	0.03MG;1.5MG	A202770	001	Feb	19,	2015	Feb	NEWA
		TABLET; ORAL-28								
		NORETHINDRONE ACETATE AND ETHI		7 000741	0.01	_ ,	0.0	0015	_ ,	
>A>	AB	FAMY CARE LTD	0.03MG; 1.5MG	A202741	001	r.ep	20,	2015	r'eb	NEWA
		ETHINYL ESTRADIOL; NORGESTREL								
		TABLET; ORAL-28								
		LOW-OGESTREL-28								
>D>		@ WATSON LABS	0.03MG;0.3MG	A075288	002	Jul	28,	1999	Feb	CMFD
>A>	AB		0.03MG;0.3MG	A075288	002	Jul	28,	1999	Feb	CMFD
		FAMOTIDINE								
		TABLET; ORAL								
\D\	7. 10	PEPCID MARATHON PHARMS	20MG	N 019462	0.01	Oat	15	1006	Fob	CAUM
		+	40MG	N 019462						
		VALEANT PHARMS NORTH	20MG	N019462						
		+	40MG	N019462						
, 11,	112	·	10110	1,019102	002	000	10,	1300	100	011111
		FENTANYL CITRATE								
		INJECTABLE; INJECTION								
		FENTANYL CITRATE PRESERVATIVE								
		+ EUROHLTH INTL SARL								
>D>	AP	+ HIKMA MAPLE	EQ 0.05MG BASE/ML	N019101	001	Jul	11,	1984	Feb	CAHN
		EL HODOLIDACTI								
		FLUOROURACIL CREAM; TOPICAL								
		CREAM, TOTICAL								
		CARAC								
>D>		CARAC + VALEANT BERMUDA	0.5%	N 020985	001	Oct	27,	2000	Feb	CAHN
>D> >A>		+ VALEANT BERMUDA	0.5% 0.5%	N 020985 N 020985						
		+ VALEANT BERMUDA								
		+ VALEANT BERMUDA								
		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION								
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK	0.5%	N 020985	001	Oct	27,	2000	Feb	CAHN
>A> >A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM	0.5% 16.545GM/50ML (330.9MG/ML)	N 020985 N 020975	001	Oct	27,	2000	Feb Feb	CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML)	N 020985 N 020975 N 020937	001	Oct Dec Dec	27, 08, 08,	2000 1999 1999	Feb Feb	CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937	001 001 001 002	Oct Dec Dec	27, 08, 08,	1999 1999 1999	Feb Feb Feb	CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937	001 001 001 002 003	Oct Dec Dec Dec	27, 08, 08, 08,	1999 1999 1999 1999	Feb Feb Feb Feb	CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937	001 001 001 002 003 004	Dec Dec Dec Dec	27, 08, 08, 08, 08,	1999 1999 1999 1999 1999	Feb Feb Feb Feb	CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937	001 001 001 002 003 004 001	Dec Dec Dec Dec Dec	27, 08, 08, 08, 08,	1999 1999 1999 1999 1999	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + MALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937	001 001 001 002 003 004 001	Dec Dec Dec Dec Dec	27, 08, 08, 08, 08, 08,	1999 1999 1999 1999 1999 1999	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + H MALLINCKRODT +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020975 N 020937	001 001 001 002 003 004 001 001	Dec Dec Dec Dec Dec Dec	27, 08, 08, 08, 08, 08,	1999 1999 1999 1999 1999 1999 1999	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + H MALLINCKRODT + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020975 N 020937 N 020937	001 001 001 002 003 004 001 001 002 003	Dec Dec Dec Dec Dec Dec Dec	27, 08, 08, 08, 08, 08, 08,	1999 1999 1999 1999 1999 1999 1999	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + + + + + + + + + + + + + + + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937	001 001 001 002 003 004 001 001 002 003	Dec Dec Dec Dec Dec Dec Dec	27, 08, 08, 08, 08, 08, 08,	1999 1999 1999 1999 1999 1999 1999	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + + + + + + + + + + + + + + + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020975 N 020937 N 020937 N 020937	001 001 002 003 004 001 002 003 004	Dec	27,, 08,, 08,, 08,, 08,, 08,, 08,, 08,,	1999 1999 1999 1999 1999 1999 1999 199	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937	001 001 002 003 004 001 002 003 004	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + LIEBEL-FLARSHEIM + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937	001 001 002 003 004 001 002 003 004 002	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + + + OPTIMARK IN PLASTIC CONTAINER + + + + + + + + + + + + + + + + + + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976 N 020976 N 020976 N 020976	001 001 002 003 004 001 002 003 004 002	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08,	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + MALLINCKRODT + + + + MALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976 N 020976 N 020976 N 020976 N 020976	001 001 002 003 004 001 002 003 004 002 003 004 001	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + + MALLINCKRODT + + + + - OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + + MALLINCKRODT + + + H MALLINCKRODT + + H MALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976 N 020976 N 020976 N 020976 N 020976 N 020976	001 001 002 003 004 001 002 003 004 001 002 003	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >A> >A> >A> >A> >D> >D>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + H MALLINCKRODT + + H MALLINCKRODT + + H MALLINCKRODT + + H MALLINCKRODT + H MALLINCKRODT + H MALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + + MALLINCKRODT + + + + - OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + + MALLINCKRODT + + + H MALLINCKRODT + + H MALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >A> >A> >A> >A> >D> >D>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + H MALLINCKRODT + + + + H MALLINCKRODT + + + + + + + + H MALLINCKRODT + + + + + + + + + + + + + + + + + + +	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >A> >A> >A> >A> >D> >D>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + H MALLINCKRODT + + H MALLINCKRODT + + H MALLINCKRODT + + H MALLINCKRODT + H MALLINCKRODT + H MALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >A> >A> >A> >A> >D> >D>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + + MALLINCKRODT + + + + + OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + HMALLINCKRODT + + + HMALLINCKRODT + + HMALLINCKRODT + HHALLINCKRODT + HHALLINCKRODT + HHALLINCKRODT + HHALLINCKRODT + HHALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A> >A> >A> >A> >A> >A> >D> >D>		+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + MALLINCKRODT + + + + - OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + HMALLINCKRODT + + + HMALLINCKRODT + HHDRALAZINE HYDROCHLORIDE INJECTABLE; INJECTION	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020937 N 020937 N 020937 N 020937 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004 001	Dec	27, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>	AP	+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + MALLINCKRODT + + + + - OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + HMALLINCKRODT + + + HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT HMALLINCKRODT	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004 001	Dec Dec Dec Dec Dec Dec Dec Apr Apr	27, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>A>	AP AP AP	+ VALEANT BERMUDA + VALEANT PHARMS NORTH GADOVERSETAMIDE INJECTABLE; INJECTION OPTIMARK + LIEBEL-FLARSHEIM + + + + MALLINCKRODT + + + + - OPTIMARK IN PLASTIC CONTAINER + LIEBEL-FLARSHEIM + + + HMALLINCKRODT + + + HMALLINCKRODT + HMALLINCKRODT + AMALLINCKRODT + HMALLINCKRODT AMALLINCKRODT HMALLINCKRODT AMALLINCKRODT AMALLI	0.5% 16.545GM/50ML (330.9MG/ML) 1654.5MG/5ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 16.545GM/50ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 3309MG/10ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 6618MG/20ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 4963.5MG/15ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML) 9927MG/30ML (330.9MG/ML)	N 020985 N 020975 N 020937 N 020976	001 001 002 003 004 001 002 003 004 001 002 003 004 001 001	Dec Dec Dec Dec Dec Dec Dec Dec Apr Jun	27, 08, 08, 08, 08, 08, 08, 08, 08	1999 1999 1999 1999 1999 1999 1999 199	Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN

		HYDROCHLOROTHIAZIDE								
		CAPSULE; ORAL								
		MICROZIDE								
>A>	AB	+ ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec	27,	1996	Feb	CAHN
>D>	AB	+ WATSON LABS	12.5MG	N020504	001	Dec	27,	1996	Feb	CAHN
		HYDROCHLOROTHIAZIDE; LISINOPRIL								
		TABLET;ORAL ZESTORETIC								
>A>	AB	ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov	18,	1993	Feb	CAHN
>A>	AB	+	12.5MG;20MG	N019888	001	Sep	20,	1990	Feb	CAHN
>A>	AB	+	25MG;20MG	N019888		_			Feb	CAHN
>D>	AB	ASTRAZENECA	12.5MG;10MG	N019888	003	Nov	18,	1993	Feb	CAHN
>D>	AB	+	12.5MG;20MG	N019888	001	Sep	20,	1990	Feb	CAHN
>D>	AB	+	25MG;20MG	N019888	002	Jul	20,	1989	Feb	CAHN
		HYDROCORTISONE								
		TABLET;ORAL HYDROCORTISONE								
>A>	AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb	23,	2015	Feb	NEWA
>A>	AB		10MG	A083365	003	Feb	23,	2015	Feb	NEWA
>D>		@	20MG	A083365	001	Jun	18,	1973	Feb	CMFD
>A>	AB		20MG	A083365	001	Jun	18,	1973	Feb	CMFD
		INSULIN GLARGINE								
>A>		SOLUTION; SUBCUTANEOUS								
>A>		TOUJEO SOLOSTAR	2001INTEC/MT /2001INTEC/MT\	MODERNO	0.01	Ech	25	2015	Ech	NTT-7577
>A>		+ SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N 206538	001	ren	23,	2015	ren	NEWA
		INSULIN GLARGINE RECOMBINANT								
>A>		SOLUTION; SUBCUTANEOUS								
>A>		TOUJEO SOLOSTAR	2001111777 / 12001111777 / 110	N 006530	0.01	m . 1.	0.5	0015	F - 1-	377773
>A>		+ SANOFI US SERVICES	300UNITS/ML (300UNITS/ML)	N206538	UUI	reb	ZJ,	2015	dea	NEWA
		IOPAMIDOL INTEGRADIE INTEGRACION								
		INJECTABLE; INJECTION								
>D>	AΡ	INJECTABLE; INJECTION ISOVUE-200	41%	N 018735	006	Jul	07.	1987	Feb	CTEC
>D> >A>	AP	INJECTABLE; INJECTION	41% 41%	N 018735 N 018735			-			
	AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO +		N 018735 N 018735			-			CTEC CTEC
		INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250			006	Jul	07,	1987	Feb	
>A>		INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250	41%	N 018735	006	Jul Jul	07,	1987 1992	Feb Feb	CTEC
>A> >D>	ΑP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO +	41% 51%	N 018735 N 018735	006 007 007	Jul Jul Jul	07, 06, 06,	1987 1992 1992	Feb Feb Feb	CTEC CTEC CTEC
>A> >D> >A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO +	41% 51% 51%	N 018735 N 018735 N 018735	006 007 007 002	Jul Jul Jul Oct	07, 06, 06, 12,	1987 1992 1992 1994	Feb Feb Feb	CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + +	41% 51% 51% 51%	N 018735 N 018735 N 018735 N 020327	006 007 007 002	Jul Jul Jul Oct	07, 06, 06, 12,	1987 1992 1992 1994	Feb Feb Feb	CTEC CTEC CTEC
>A> >D> >A> >D> >A> >D> >A> >D>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + +	41% 51% 51% 51%	N 018735 N 018735 N 018735 N 020327	006 007 007 002 002	Jul Jul Jul Oct Oct	07, 06, 06, 12,	1987 1992 1992 1994 1994	Feb Feb Feb Feb	CTEC CTEC CTEC CTEC
>A> >D> >A> >D> >A> >D> >A> >D>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO	41% 51% 51% 51% 51%	N 018735 N 018735 N 018735 N 020327 N 020327	006 007 007 002 002	Jul Jul Oct Oct	07, 06, 06, 12, 12,	1987 1992 1992 1994 1994	Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC
>A> >D> >A> >D> >A> >D> >D> >D>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO	41% 51% 51% 51% 61%	N 018735 N 018735 N 018735 N 020327 N 020327	006 007 007 002 002	Jul Jul Oct Oct	07, 06, 06, 12, 12,	1987 1992 1992 1994 1994	Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC
>A> >D> >A> >A> >D> >A> >D> >A> >D> >A> >A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO +	41% 51% 51% 51% 61% 61%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327	006 007 007 002 002 003 003	Jul Jul Oct Oct Oct Oct	07, 06, 06, 12, 12, 12,	1987 1992 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A> >D> >A> >A> >D> >A> >D> >A> >D> >A> >A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370	41% 51% 51% 51% 61%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327	006 007 007 002 002 003 003	Jul Jul Oct Oct Oct Oct	07, 06, 06, 12, 12, 12,	1987 1992 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A> >D> >A> >D> >A> >D> >A> >D> >A> >D> >A> >D> >A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO	41% 51% 51% 51% 61% 61%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327	006 007 007 002 002 003 003	Jul Jul Oct Oct Oct Oct	07, 06, 06, 12, 12, 12,	1987 1992 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A> >D> >A> >D> >A> >D> >A> >D> >A> >D> >A> >D> >A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO +	41% 51% 51% 51% 61% 61%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327	006 007 007 002 002 003 003	Jul Jul Oct Oct Oct Oct	07, 06, 06, 12, 12, 12,	1987 1992 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A> >D> >A> >D> >A> >D> >A> >D> >A> >D> >A> >D> >A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + INDECTABLE; INJECTION	41% 51% 51% 51% 61% 61%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327	006 007 007 002 002 003 003 004 004	Jul Jul Oct Oct Oct Oct Oct	07, 06, 06, 12, 12, 12, 12,	1987 1992 1992 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + IOTHALAMATE MEGLUMINE INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT	41% 51% 51% 51% 61% 61% 76%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327	006 007 007 002 003 003 004 004	Jul Jul Oct Oct Oct Oct Aug	07, 06, 06, 12, 12, 12, 12,	1987 1992 1992 1994 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 30	41% 51% 51% 51% 61% 61% 76% 76%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327	006 007 007 002 003 003 004 004	Jul Jul Oct Oct Oct Oct Aug Aug	07, 06, 06, 12, 12, 12, 12, 12,	1987 1992 1994 1994 1994 1994 1994 1994	Feb Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + IOTHALAMATE MEGLUMINE INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 30 + LIEBEL-FLARSHEIM	41% 51% 51% 51% 61% 61% 76% 76% 30%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327	006 007 007 002 003 003 004 004	Jul Jul Oct Oct Oct Oct Aug Aug	07, 06, 06, 12, 12, 12, 12, 16, 16,	1987 1992 1994 1994 1994 1994 1994 1994 1962 1962	Feb Feb Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + IOTHALAMATE MEGLUMINE INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 30 + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 43	41% 51% 51% 51% 61% 61% 76% 76% 30%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327 N 013295 N 013295 N 016983 N 016983	006 007 007 002 003 003 004 004 001	Jul Jul Oct Oct Oct Oct Aug Aug Aug	07, 06, 06, 12, 12, 12, 12, 16, 16, 06, 06,	1987 1992 1994 1994 1994 1994 1994 1992 1962 1971 1971	Feb Feb Feb Feb Feb Feb Feb Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + LICTHALAMATE MEGLUMINE INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 30 + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 43 + LIEBEL-FLARSHEIM	41% 51% 51% 51% 61% 61% 76% 76% 30% 30% 30%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327 N 013295 N 016983 N 016983 N 013295	006 007 007 002 003 003 004 004 001 001	Jul Jul Oct Oct Oct Oct Aug Aug Aug Aug	07, 06, 06, 12, 12, 12, 12, 16, 06, 06,	1987 1992 1994 1994 1994 1994 1994 1994 1962 1962 1971 1978	Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + LISOVUE-370 + BRACCO + ISOVUE-370 + BRAC	41% 51% 51% 51% 61% 61% 76% 76% 30%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327 N 013295 N 013295 N 016983 N 016983	006 007 007 002 003 003 004 004 001 001	Jul Jul Oct Oct Oct Oct Aug Aug Aug Aug	07, 06, 06, 12, 12, 12, 12, 16, 06, 06,	1987 1992 1994 1994 1994 1994 1994 1994 1962 1962 1971 1978	Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + LICTHALAMATE MEGLUMINE INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 30 + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 43 + LIEBEL-FLARSHEIM	41% 51% 51% 51% 61% 61% 76% 76% 30% 43% 43%	N018735 N018735 N018735 N020327 N020327 N020327 N020327 N020327 N020327 N013295 N013295 N016983 N016983 N013295 N013295	006 007 007 002 003 003 004 004 001 001 001 002 002	Jul Jul Oct Oct Oct Oct Aug Aug Aug Aug Aug	07, 06, 06, 12, 12, 12, 12, 16, 06, 06, 29,	1987 1992 1994 1994 1994 1994 1994 1992 1962 1971 1978 1978	Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC
>A>	AP AP	INJECTABLE; INJECTION ISOVUE-200 + BRACCO + ISOVUE-250 + BRACCO + + + + ISOVUE-300 + BRACCO + ISOVUE-370 + BRACCO + ISOVUE-370 + BRACCO + IOTHALAMATE MEGLUMINE INJECTABLE; INJECTION CONRAY + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 30 + LIEBEL-FLARSHEIM + MALLINCKRODT CONRAY 43 + LIEBEL-FLARSHEIM + MALLINCKRODT SOLUTION; INTRAVESICAL	41% 51% 51% 51% 61% 61% 76% 76% 30% 30% 30%	N 018735 N 018735 N 018735 N 020327 N 020327 N 020327 N 020327 N 020327 N 020327 N 013295 N 016983 N 016983 N 013295	006 007 007 002 003 003 004 004 001 001 001 002 002	Jul Jul Oct Oct Oct Oct Aug Aug Aug Aug Aug	07, 06, 06, 12, 12, 12, 12, 16, 29, 25,	1987 1992 1994 1994 1994 1994 1994 1992 1971 1978 1978	Feb	CTEC CTEC CTEC CTEC CTEC CTEC CTEC CTEC

	IOVERSOL								
	INJECTABLE; INJECTION								
	OPTIRAY 160								
>A>	@ LIEBEL-FLARSHEIM	34%	N019710	003	Dec	30,	1988	Feb	CAHN
>D>	@ MALLINCKRODT OPTIRAY 240	34%	N 019710	003	Dec	30,	1988	Feb	CAHN
>A>	+ LIEBEL-FLARSHEIM	51%	N019710	002	Dec	30,	1988	Feb	CAHN
>A>	@	51%	N020923	001	Мау	28,	1998	Feb	CAHN
>D>	+ MALLINCKRODT	51%	N019710	002	Dec	30,	1988	Feb	CAHN
>D>	@	51%	N020923	001	May	28,	1998	Feb	CAHN
	OPTIRAY 300								
>A>	+ LIEBEL-FLARSHEIM	64%	N019710	004	Jan	22,	1992	Feb	CAHN
>A>	+	64%	N020923	004	May	13,	1999	Feb	CAHN
>D>	+ MALLINCKRODT	64%	N019710	004	Jan	22,	1992	Feb	CAHN
>D>	+	64%	N020923	004	Мау	13,	1999	Feb	CAHN
	OPTIRAY 320								
>A>	+ LIEBEL-FLARSHEIM	68%	N019710			-			CAHN
>A>	@	68%	N020923		-				CAHN
>D>	+ MALLINCKRODT	68%	N019710						CAHN
>D>	@	68%	N020923	002	May	29,	1998	Feb	CAHN
> 7 >	OPTIRAY 350	7.40	NI 01 071 0	005	T	2.2	1000	D = l=	CALINI
>A> >A>	+ LIEBEL-FLARSHEIM +	74% 74%	N 019710						CAHN CAHN
			N 020923		-				
>D> >D>	+ MALLINCKRODT +	74% 74%	N 019710 N 020923						CAHN CAHN
707	т	746	N 020923	003	мау	۷0,	1990	reb	CARN
	IRBESARTAN								
	TABLET; ORAL								
	IRBESARTAN								
>A> AB	JUBILANT GENERICS	75MG	A203534	001	Feb	23,	2015	Feb	NEWA
>A> AB		150MG	A203534	002	Feb	23,	2015	Feb	NEWA
>A> AB		300MG	A203534	003	Feb	23,	2015	Feb	NEWA
	<u>ISOSORBIDE DINITRATE</u>								
	TABLET; ORAL								
\D\ 1D	TABLET;ORAL ISORDIL	EMO	N.010000	007	- 1	2.0	1000	n.1.	02.1121
>D> AB	TABLET;ORAL ISORDIL VALEANT BERMUDA	5MG	N 012093						CAHN
>D>	TABLET;ORAL ISORDIL VALEANT BERMUDA @	10MG	N012093	002	Jul	29,	1988	Feb	CAHN
>D> >D>	TABLET;ORAL ISORDIL VALEANT BERMUDA @ @	10MG 20MG	N 012093 N 012093	002 006	Jul Jul	29 , 29 ,	1988 1988	Feb Feb	CAHN CAHN
>D> >D> >D>	TABLET;ORAL ISORDIL VALEANT BERMUDA @ @ @	10MG 20MG 30MG	N 012093 N 012093 N 012093	002 006 005	Jul Jul Jul	29, 29, 29,	1988 1988 1988	Feb Feb Feb	CAHN CAHN CAHN
>D> >D> >D> >D>	TABLET;ORAL ISORDIL VALEANT BERMUDA @ @ @ @ #	10MG 20MG 30MG 40MG	N 012093 N 012093 N 012093 N 012093	002 006 005 001	Jul Jul Jul Jul	29, 29, 29, 29,	1988 1988 1988 1988	Feb Feb Feb	CAHN CAHN CAHN
>D> >D> >D> >D> >A> AB	TABLET; ORAL ISORDIL VALEANT BERMUDA 0 0 0 + VALEANT PHARMS NORTH	10MG 20MG 30MG 40MG 5MG	N 012093 N 012093 N 012093 N 012093 N 012093	002 006 005 001 007	Jul Jul Jul Jul	29, 29, 29, 29,	1988 1988 1988 1988 1988	Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >D> >A> A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @	10MG 20MG 30MG 40MG 5MG 10MG	N 012093 N 012093 N 012093 N 012093 N 012093 N 012093	002 006 005 001 007 002	Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @	10MG 20MG 30MG 40MG 5MG 10MG 20MG	N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006	Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA 0 0 0 + VALEANT PHARMS NORTH 0 0 0	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005	Jul Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @	10MG 20MG 30MG 40MG 5MG 10MG 20MG	N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005	Jul Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA 0 0 0 + VALEANT PHARMS NORTH 0 0 0 + + + +	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005	Jul Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA 0 0 0 + VALEANT PHARMS NORTH 0 0 0	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005	Jul Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ # VALEANT PHARMS NORTH @ @ @ # ISOTRETINOIN	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005	Jul Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ # VALEANT PHARMS NORTH @ @ @ # ISOTRETINOIN CAPSULE; ORAL	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Jul Jul	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ # VALEANT PHARMS NORTH @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Jul Aug	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ # VALEANT PHARMS NORTH @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Jul Aug	29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Aug Aug	29, 29, 29, 29, 29, 29, 29, 29, 15,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Aug Aug	29, 29, 29, 29, 29, 29, 29, 29, 15,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Aug Aug	29, 29, 29, 29, 29, 29, 29, 29, 15,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHR: SOLUTION; IRRIGATION	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Aug Aug	29, 29, 29, 29, 29, 29, 29, 29, 15,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 30MG 40MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 006 005 001	Jul Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHR: SOLUTION; IRRIGATION	1 0 MG 2 0 MG 3 0 MG 4 0 MG 5 MG 1 0 MG 2 0 MG 3 0 MG 4 0 MG	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093	002 006 005 001 007 006 005 001	Jul Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 29,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 30MG 40MG ESPECIAL SEPECIAL SE	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N021951 N021951 A202099	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 30,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >D> >A> AB >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHRE SOLUTION; IRRIGATION OMIDRIA + OMEROS	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 40MG 25MG 30MG 40MG Expression of the second of the s	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N021951 N021951 A202099	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 30,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >A> AB >A> >A> >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHR SOLUTION; IRRIGATION OMIDRIA + OMEROS +	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 40MG 25MG 30MG 40MG Expression of the second of the se	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N021951 N021951 A202099	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 30,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >A> AB >A> >A> >A> >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHR SOLUTION; IRRIGATION OMIDRIA + OMEROS + LAMIVUDINE; RALTEGRAVIR POTASSIUM	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 40MG 25MG 30MG 40MG Expression of the state of the	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N021951 N021951 A202099	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 30,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >A> AB >A> >A> >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHR SOLUTION; IRRIGATION OMIDRIA + OMEROS + LAMIVUDINE; RALTEGRAVIR POTASSIUM TABLET; ORAL	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 40MG 25MG 30MG 40MG Expression of the state of the	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N021951 N021951 A202099	002 006 005 001 007 002 006 005 001	Jul Jul Jul Jul Jul Jul Jul Feb	29, 29, 29, 29, 29, 29, 29, 29, 29, 30,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN
>D> >D> >D> >A> AB >A> >A> >A> >A> >A> >A> >A> >A>	TABLET; ORAL ISORDIL VALEANT BERMUDA @ @ @ @ @ # VALEANT PHARMS NORTH @ @ @ @ # ISOTRETINOIN CAPSULE; ORAL ABSORICA RANBAXY ZENATANE DR REDDYS LABS LTD KETOROLAC TROMETHAMINE; PHENYLEPHR SOLUTION; IRRIGATION OMIDRIA + OMEROS + LAMIVUDINE; RALTEGRAVIR POTASSIUM	10MG 20MG 30MG 40MG 5MG 10MG 20MG 30MG 40MG 40MG 25MG 30MG 40MG Expression of the state of the	N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N012093 N021951 N021951 A202099 N205388 N205388	002 006 005 001 007 006 005 001	Jul Jul Jul Jul Jul Jul Jul Mag Aug May	29, 29, 29, 29, 29, 29, 29, 29, 30, 30,	1988 1988 1988 1988 1988 1988 1988 1988	Feb Feb Feb Feb Feb Feb Feb Feb Feb	CAHN CAHN CAHN CAHN CAHN CAHN CAHN CAHN

>A>		LENVATINIB MESYLATE								
>A>		CAPSULE; ORAL								
>A> >A>		LENVIMA EISAI INC	EO 4MG BASE	N206947	0.01	Foh	13	2015	Foh	NEWA
>A>		+	EQ 10MG BASE	N206947			-			
/ []		'	EQ 10NG DAGE	11 200347	002	reb	13,	2015	reb	MEMA
		LEVETIRACETAM								
		TABLET, EXTENDED RELEASE; ORAL								
		LEVETIRACETAM								
>A>		APOTEX INC	1GM	A202958	001	Feb	25,	2015	Feb	NEWA
		LEVOCETIRIZINE DIHYDROCHLORIDE								
		TABLET; ORAL								
		LEVOCETIRIZINE DIHYDROCHLORIDE	Eve	3 000000	0.01	- 1	10	0015	- 1	
>A>	AB	APOTEX INC	5MG	A203027	001	r'eb	13,	2015	r'eb	NEWA
		LEVOLEUCOVORIN CALCIUM								
		SOLUTION; IV (INFUSION)								
>A>		LEVOLEUCOVORIN CALCIUM								
>A>		SANDOZ	EQ 175MG BASE/17.5ML (EQ 10MG	A203563	001	Mar	09,	2015	Feb	NEWA
			BASE/ML)							
>A>			EQ 250MG BASE/25ML (EQ 10MG	A203563	002	Mar	09,	2015	Feb	NEWA
			BASE/ML)							
		LEVONORGESTREL								
		INTRAUTERINE DEVICE; INTRAUTERINE								
>A>		LILETTA								
>A>		MEDICINES360	52MG	N206229	001	Feb	26,	2015	Feb	NEWA
		LIDOCAINE HYDROCHLORIDE								
		INJECTABLE; INJECTION								
		LIDOCAINE HYDROCHLORIDE PRESERVA		3.004605	0.01	. .	1.0	1075	T . 1.	G 2 1131
>A>		@ EUROHLTH INTL SARL	1%	A 084625						
>A> >D>		0 0 HIKMA MAPLE	2% 1%	A 084625 A 084625			-		Feb Feb	
>D>		e HIAMA MAPLE	2%	A 084625			-		Feb	
7 07		e	2 0	11004025	002	Oun	10,	1373	100	CITIIN
		LIDOCAINE; PRILOCAINE								
		CREAM; TOPICAL								
		EMLA								
>A>	AB	+ ACTAVIS LABS UT INC	2.5%;2.5%	N019941	001	Dec	30,	1992	Feb	CAHN
>D>	AB	+ WATSON LABS INC	2.5%;2.5%	N019941	001	Dec	30,	1992	Feb	CAHN
		LISINOPRIL								
		TABLET; ORAL								
>A>	7\ TO	ZESTRIL ALVOGEN IPCO SARL	2.5MG	N 019777	005	۵nr	20	1003	Foh	CVRV
>A>		ALVOGEN IFCO SARL	5MG	N 019777		_				CAHN
>A>			10MG	N 019777		_				CAHN
>A>			20MG	N 019777		-	-			CAHN
>A>			30MG	N 019777		_				CAHN
>A>		+	40MG	N 019777			•			CAHN
>D>		ASTRAZENECA	2.5MG	N 019777		-	-			CAHN
>D>			5MG	N 019777		-	-			CAHN
>D>			10MG	N 019777		-	-			CAHN
>D>			20MG	N 019777		-	-			CAHN
>D>			30MG	N 019777		-	-			CAHN
>D>		+	4 0 MG	N019777			-			CAHN
						_	•			
		<u>LITHIUM CARBONATE</u>								
		TABLET, EXTENDED RELEASE; ORAL								
	_	LITHIUM CARBONATE	45.000	- 0 - 1				0	_	
>D>	AB	HIKMA INTL PHARMS	450MG	A076490			-			
>A>		@	450MG	A076490	001	Jun	17,	2003	Feb	DISC

		LOSARTAN POTASSIUM								
		TABLET; ORAL								
		LOSARTAN POTASSIUM							_	
>D>		@ WATSON LABS	25MG	A091129						
>A>	AB		25MG	A 0 9 1 1 2 9						CMFD
>D>	7 10	@	50MG	A091129 A091129						CMFD CMFD
>A> >D>	AB	@	50MG 100MG	A 0 9 1 1 2 9 A 0 9 1 1 2 9						CMFD
>A>	7/ T2	e e	100MG 100MG	A 0 9 1 1 2 9 A 0 9 1 1 2 9			-			CMFD
/11/	AD		100119	NOJIIZJ	003	OCL	00,	2010	reb	CMFD
		MEPERIDINE HYDROCHLORIDE								
		INJECTABLE; INJECTION								
		MEPERIDINE HYDROCHLORIDE								
>A>	AP	EUROHLTH INTL SARL	25MG/ML	A080445	001	Jan	22,	1975	Feb	CAHN
>A>	AP		50MG/ML	A080445					Feb	CAHN
>A>			75MG/ML	A080445			-			CAHN
>A>			100MG/ML	A080445			-			CAHN
>D>		HIKMA MAPLE	25MG/ML	A 080445			-			CAHN
>D>			50MG/ML	A 080445						CAHN
>D> >D>			75MG/ML 100MG/ML	A 080445 A 080445						CAHN CAHN
707	AP		IOOMG/ML	AU0U443	004	Jan	ZZ,	1973	reb	CARN
		METAXALONE								
		TABLET; ORAL								
		METAXALONE								
>A>		COREPHARMA	400MG	A040486	001	Feb	27,	2015	Feb	NEWA
		METHYLPHENIDATE HYDROCHLORIDE								
		CAPSULE, EXTENDED RELEASE;ORAL RITALIN LA								
>D>	AB1	+ NOVARTIS	40MG	N 021284	003	Jun	05,	2002	Feb	CRLD
>A>	AB1		40MG	N021284			-			CRLD
>D>			60MG	N021284	005	Oct	27,	2014	Feb	CRLD
>A>		+	60MG	N021284	005	Oct	27,	2014	Feb	CRLD
		TABLET, CHEWABLE; ORAL								
		METHYLIN								
>D>		MALLINCKRODT	2.5MG	N 021475		_				
>A>	AB		2.5MG	N 021475		-				CFTG
>D>			5MG	N 021475		_				CFTG
>A>	AB		5MG	N 021475		_				CFTG
>D>	7.10	+	10MG 10MG	N 021475		-	-			CFTG
>A> >A>		* METHYLPHENIDATE HYDROCHLORIDE	PLIOT	N 021475	003	wht	1J,	2003	ren	CFTG
>A>		NOVEL LABS INC	2.5MG	A204115	001	Feb	25,	2015	Feb	NEWA
>A>			5MG	A204115			•			
>A>	AB		10MG	A204115			-			
		METRONIDAZOLE								
		CREAM; TOPICAL NORITATE								
>D>		+ VALEANT BERMUDA	1%	N020743	001	Sep	26,	1997	Feb	CAHN
>A>		+ VALEANT PHARMS NORTH	1%	N020743	001	Sep	26,	1997	Feb	CAHN
		GEL; VAGINAL								
>A>		METRONIDAZOLE	1.3%	N 205223	0.01	M ~	24	2014	Fah	C 7 IINI
>A>		+ ACTAVIS LABS UT INC + WATSON LABS INC	1.3%	N 205223						
>A>		NUVESSA	±.50	14 5 0 0 5 5 5	001	HAL	47,	2017	T CD	C21111N
		= = = = .	4.00						_	

N205223 001 Mar 24, 2014 Feb CTNA

>A> + ACTAVIS LABS UT INC 1.3%

		MIGLITOL TABLET; ORAL GLYSET								
>D>		PHARMACIA AND UPJOHN	25MG	N 020682	001	Dec	1.8	1996	Feh	CETG
>A>	7. 7.	Timidmotil Tivb of Colin	25MG	N 020682						
>D>	AA		50MG	N 020682			-		Feb	
	70.70									
>A>			50MG	N 020682			-		Feb	
>D>			100MG	N 020682			-		Feb	
>A>			100MG	N 020682	003	Dec	18,	1996	Feb	CFTG
		MIGLITOL				_				
>A>		ORIENT PHARMA CO LTD	25MG	A203965			-		Feb	
>A>			50MG	A203965						
>A>	AA		100MG	A203965	003	Feb	24,	2015	Feb	NEWA
		MONTELUKAST SODIUM TABLET, CHEWABLE; ORAL MONTELUKAST SODIUM								
>A>	AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb	27,	2015	Feb	NEWA
>A>	AB		EQ 5MG BASE	A203795	002	Feb	27,	2015	Feb	NEWA
>A>	AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar	12,	2015	Feb	NEWA
>A>	AB		EQ 5MG BASE	A203582	002	Mar	12,	2015	Feb	NEWA
		MOXIFLOXACIN HYDROCHLORIDE								
		SOLUTION/DROPS; OPHTHALMIC								
		MOXIFLOXACIN HYDROCHLORIDE								
>A>	AT	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar	06,	2015	Feb	NEWA
		OLANZAPINE TABLET, ORALLY DISINTEGRATING; ORA OLANZAPINE								
>A>		MACLEODS PHARMS LTD	5MG	A203044	001	Feb	20,	2015	Feb	NEWA
>A>	AB		10MG	A203044	002	Feb	20,	2015	Feb	NEWA
>A>	AB		15MG	A203044	003	Feb	20,	2015	Feb	NEWA
>A>	AB		20MG	A203044	004	Feb	20,	2015	Feb	NEWA
>A>	AB	ORCHID HLTHCARE	5MG	A202937	001	Mar	02,	2015	Feb	NEWA
>A>	AB		10MG	A202937	002	Mar	02,	2015	Feb	NEWA
>A>	AB		15MG	A202937	003	Mar	02,	2015	Feb	NEWA
>A>	AB		20MG	A202937	004	Mar	02,	2015	Feb	NEWA
		OXYTOCIN								
		INJECTABLE; INJECTION OXYTOCIN								
>A>		+ EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)			_				
>A>	AP	+	100USP UNITS/10ML (10USP UNITS/ML)	N 018243	002	Jan	10,	2007	Feb	CAHN
>D>	AP	+ HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)	N018243	001	Apr	29,	1980	Feb	CAHN
>D>	ΑP	+	100USP UNITS/10ML (10USP	N018243	002	Jan	10,	2007	Feb	CAHN
			UNITS/ML)							
>A>		PALBOCICLIB								
>A>		CAPSULE; ORAL								
>A>		IBRANCE	75MG	N 207102	0.01	T = l=	0.2	2015	D-l-	3117177
>A>		PFIZER INC		N 207103			-			
>A>			100MG	N 207103			-			
>A>		+	125MG	N207103	003	гер	03,	2015	reb	NEWA
>A>		PANOBINOSTAT								
>A>		CAPSULE; ORAL								
>A>		FARYDAK								
>A>		NOVARTIS PHARMS CORP	10MG	N 205353	0.01	Feh	23-	2015	Feh	NEWA
>A>		1.5 (III.I I I I I I I I I I I I I I I I I	15MG	N 205353						
>A>		+	20MG	N 205353			-			
///		•	20110	11 200000	000	r en	۷,	2010	r. GD	TATE AALT
		PENTOXIFYLLINE TABLET, EXTENDED RELEASE; ORAL								
		PENTOXIFYLLINE	400250	3.055655	0.0 -		0.0	100-		~
>D>		VALEANT BERMUDA	400MG	A075028			-			
>A>	AB	VALEANT PHARMS	400MG	A075028	001	Jul	20,	1998	Feb	CAHN

		PHENYTOIN SODIUM								
		INJECTABLE; INJECTION								
		PHENYTOIN SODIUM								
>A>	ΑP	+ EUROHLTH INTL SARL	50MG/ML	A084307	001	Jul	16,	1975	Feb	CAHN
>D>	AP	+ HIKMA MAPLE	50MG/ML	A084307	001	Jul	16,	1975	Feb	CAHN
		PIRFENIDONE								
		CAPSULE; ORAL								
		ESBRIET								
>A>		+ GENENTECH INC	267MG	N022535	001	Oct	15,	2014	Feb	CAHN
>D>		+ INTERMUNE INC	267MG	N022535	001	Oct	15,	2014	Feb	CAHN
		PODOFILOX								
		GEL; TOPICAL								
		CONDYLOX								
>A>			0.5%	N020529	001	Mar	13,	1997	Feb	CAHN
>D>		+ WATSON PHARMS	0.5%	N020529						
		POTASSIUM CHLORIDE								
		TABLET, EXTENDED RELEASE; ORAL								
		POTASSIUM CHLORIDE								
>D>	AB2	MYLAN PHARMS INC	8.OMEQ	A204662	001	Aug	21,	2014	Feb	CPOT
>A>			8MEQ	A204662		_				
>D>	AB2		10.0MEQ	A204662		_				
>A>			10MEO	A204662		_	-			
, 11,	1122		1011126	11201002	002	1149	,	2011	200	0101
		PROCHLORPERAZINE EDISYLATE								
		INJECTABLE; INJECTION								
		PROCHLORPERAZINE EDISYLATE								
>A>	AP	+ EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug	29,	1989	Feb	CAHN
>D>	AP	+ HIKMA MAPLE	EQ 5MG BASE/ML	A089903	001	Aug	29,	1989	Feb	CAHN
		PROGESTERONE								
		GEL; VAGINAL								
		CRINONE	40	27.000.00.01	0.01		0.1	1007		~~
>A>		ACTAVIS LABS UT INC	4%	N 020701			-			
>A>		+	8%	N020701			-		Feb	
>D>		WATSON LABS	4%	N020701			-			CAHN
>D>		+	8%	N020701	002	Jul	31,	1997	Feb	CAHN
		SODIUM CHLORIDE								
		INJECTABLE; INJECTION								
		SODIUM CHLORIDE 0.9%								
>A>	ΑP	EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan	20,	2012	Feb	CAHN
>D>	ΑP	HIKMA (MAPLE)	9MG/ML	A201850	001	Jan	20,	2012	Feb	CAHN
		SODIUM CHLORIDE 0.9%								
>A>		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep	24,	2013	Feb	CAHN
>D>		HIKMA MAPLE	9MG/ML	A201833	001	Sep	24,	2013	Feb	CAHN
		SODIUM CHLORIDE 0.9% IN PLASTIC								
>A>		+ LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul	27,	2006	Feb	CAHN
>A>			112.5MG/125ML (9MG/ML)	N021569	002	Jul	27,	2006	Feb	CAHN
>A>		+	405MG/50ML (9MG/ML)	N021569	001	Jul	27,	2006	Feb	CPOT
>A>			1012.5MG/125ML (9MG/ML)	N021569	002	Jul	27,	2006	Feb	CPOT
>D>		+ MALLINCKRODT	45MG/50ML (9MG/ML)	N021569	001	Jul	27,	2006	Feb	CAHN
>D>			112.5MG/125ML (9MG/ML)	N021569	002	Jul	27,	2006	Feb	CAHN
		SODIUM FLUORIDE F-18								
		INJECTABLE; INTRAVENOUS								
		SODIUM FLUORIDE F-18								
>A>	AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb	27,	2015	Feb	NEWA
		TERBINAFINE HYDROCHLORIDE								
		TABLET; ORAL								
		TERBINAFINE HYDROCHLORIDE								
>D>				A078229						
>A>		@	EQ 250MG BASE	A078229	001	Jul	02,	2007	Feb	DISC

		TETRABENAZINE								
		TABLET; ORAL								
		XENAZINE								
>D>		VALEANT BERMUDA	12.5MG	N021894	001	Aug	15,	2008	Feb	CAHN
>D>		+	25MG	N021894	002	Aug	15,	2008	Feb	CAHN
>A>		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug	15,	2008	Feb	CAHN
>A>		+	25MG	N021894	002	Aug	15,	2008	Feb	CAHN
		TOBRAMYCIN								
		SOLUTION; INHALATION KITABIS PAK								
>D>		+ PULMOFLOW INC	300MG/5ML	N205433	001	Dec	02	2014	Feh	CTEC
>A>	ΔN	TOERIOT HOW TWO	300MG/5ML	N 205433			-			
/ []	TIN		500rig/ Srifi	N 200433	001	Dec	02,	2014	reb	CIEC
		TOLTERODINE TARTRATE								
		TABLET; ORAL								
		TOLTERODINE TARTRATE								
>A>		IVAX SUB TEVA PHARMS	1MG	A077006			-		Feb	NEWA
>A>	AB		2MG	A077006	002	Feb	23,	2015	Feb	NEWA
		VENLAFAXINE HYDROCHLORIDE								
		CAPSULE, EXTENDED RELEASE; ORAL								
		VENLAFAXINE HYDROCHLORIDE								
>D>	AB	VALEANT BERMUDA	EQ 37.5MG BASE	A090071	001	Apr	15,	2011	Feb	CAHN
>D>	AB		EQ 75MG BASE	A090071	002	Apr	15,	2011	Feb	CAHN
>D>	AB		EQ 150MG BASE	A090071	003	Apr	15,	2011	Feb	CAHN
>A>	AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr	15,	2011	Feb	CAHN
>A>	AB		EQ 75MG BASE	A090071	002	Apr	15,	2011	Feb	CAHN
>A>	AB		EQ 150MG BASE	A090071	003	Apr	15,	2011	Feb	CAHN
		ZAFIRLUKAST								
		TABLET; ORAL								
		ACCOLATE								
>D>	AB	ASTRAZENECA	10MG	N020547		-	-		Feb	CAHN
>D>	AB	+	20MG	N020547		-	-		Feb	CAHN
>A>	AB	PAR PHARM INC	10MG	N020547		-	-		Feb	CAHN
>A>	AB	+	20MG	N020547	001	Sep	26,	1996	Feb	CAHN

ADDITIONS/DELETIONS FOR OTC DRUG PRODUCT LIST

	TABLET, CHEWABLE; ORAL							
>D>	CETIRIZINE HYDROCHLORIDE A	LLERGY						
>D>	SANDOZ	5MG	A078692	001	Feb 14,	2008	Feb	CTNA
>D>	+	10MG	A078692	002	Feb 14,	2008	Feb	CTNA
	CHILDREN'S CETIRIZINE HYDR	OCHLORIDE ALLERGY						
>A>	JUBILANT GENERICS	5MG	A091116	001	Feb 19,	2015	Feb	NEWA
>A>		10MG	A091116	002	Feb 19,	2015	Feb	NEWA
>A>	SANDOZ	5MG	A078692	001	Feb 14,	2008	Feb	CTNA
>A>	+	10MG	A078692	002	Feb 14,	2008	Feb	CTNA
	CHILDREN'S CETIRIZINE HYDR	OCHLORIDE HIVES RELIEF						
>A>	JUBILANT GENERICS	5MG	A091116	003	Feb 19,	2015	Feb	NEWA
>A>		10MG	A091116	004	Feb 19,	2015	Feb	NEWA
	KETOTIFEN FUMARATE							
	SOLUTION/DROPS; OPHTHALMIC							
	ALAWAY							
>A>	BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11,	2015	Feb	NEWA
	NAPROXEN SODIUM							
	CAPSULE; ORAL							
	NAPROXEN SODIUM							
>A>	CATALENT	EQ 200MG BASE	A202807	001	Feb 13,	2015	Feb	NEWA

CURRENT MONTH ADDS/DELETES LIST NOTE:

CETIRIZINE HYDROCHLORIDE

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>.

The change code description:

NEWA	New drug product approval usually in the supplement month.				
CAHN	Applicant holder firm name has changed.				
CAIN	hange. There has been a change in the Ingredient(s) name. All products will be deleted under the				
	old name and all products will be added under the changed ingredient(s) name.				
CDFR	Change. Dosage Form; Route of Administration.				
CFTG	Change. A first time generic for the innovator product. A TE Code is added.				
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.				
CMS1	Change. Miscellaneous addition to list.				
CMS2	Change. Miscellaneous deletion from list.				
CPOT	Change. Potency amount/unit.				
CRLD	Change. Reference Listed Drug.				
CTEC	Change. Therapeutic Equivalence Code.				
CTNA	Change. Trade Name.				
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the				
	discontinued section in the next edition.				